Figure 3
Figure 3. CBL and TP53 mutations and EVI1 and WT1 expression in patients progressing to acute leukemia. (A) CBL mutation in patient 9 showing detection of the mutation in CD41+ megakaryocytes 2 years before AML transformation and loss of the wild-type CBL allele in leukemic blasts. (B) TP53 mutations in 3 patients progressing to acute leukemia showing the presence of the mutation 1 year before transformation in patient 11. (C) EVI1 expression measured by real-time PCR normalized to normal CD34+ cells showing a 17-fold increase in relative EVI1 expression in patient 2. (D) WT1 expression measured by real-time PCR normalized to normal CD34+ cells showing increased transcript levels (>2 standard deviations above the mean of the normal controls) in 6 of 7 JAK2-mutant and 5 of 6 JAK2 wild-type leukemias. Grans indicates purified granulocytes; and mon, months.

CBL and TP53 mutations and EVI1 and WT1 expression in patients progressing to acute leukemia. (A) CBL mutation in patient 9 showing detection of the mutation in CD41+ megakaryocytes 2 years before AML transformation and loss of the wild-type CBL allele in leukemic blasts. (B) TP53 mutations in 3 patients progressing to acute leukemia showing the presence of the mutation 1 year before transformation in patient 11. (C) EVI1 expression measured by real-time PCR normalized to normal CD34+ cells showing a 17-fold increase in relative EVI1 expression in patient 2. (D) WT1 expression measured by real-time PCR normalized to normal CD34+ cells showing increased transcript levels (>2 standard deviations above the mean of the normal controls) in 6 of 7 JAK2-mutant and 5 of 6 JAK2 wild-type leukemias. Grans indicates purified granulocytes; and mon, months.

Close Modal

or Create an Account

Close Modal
Close Modal